Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
Subscribe To Our Newsletter & Stay Updated
